

*The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



天津泰達生物醫學工程股份有限公司  
**Tianjin TEDA Biomedical Engineering Company Limited**  
*(a joint stock company incorporated in the People's Republic of China with limited liability)*  
(Stock code: 8189)

## **DISCLOSEABLE TRANSACTION SUPPLEMENTAL ANNOUNCEMENT**

Reference is made to the announcement of Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”) dated 28 December 2021 in relation to the entering into the Equity Transfer Agreement between the Company and the Purchaser, pursuant to which the Company agreed to sell 30.2653% equity interest in Tianjin Alpha to the Purchaser at a cash consideration of RMB10,860,000 (approximately HK\$13,290,000). In order to ensure the timely performance of the Equity Transfer Agreement, the Company entered into the Equity Pledge Agreements (the “**Previous Announcement**”) with the Purchaser and Tianjin Huyanglin, respectively. Unless the context otherwise requires, terms used in this announcement shall have the same meanings as those ascribed to them in the Previous Announcement.

The Company hereby provides further information in relation to the Transaction and set out as follows:

- (i) The Purchaser is Mr. Wang Shuxin (“**Mr. Wang**”) who, to the best of the Directors’ knowledge, information and belief after having made all reasonable enquiries, is an independent third party of the Company.
- (ii) As at the date of the Previous Announcement, Tianjin Huyanglin was owned as to 61% by Mr. Wang and 39% by Tianjin Ruigu Technology Development Company Limited (“**Tianjin Ruigu**”). Tianjin Ruigu was a company 100%-owned by Mr. Zhang Zongli (“**Mr. Zhang**”). Mr. Zhang is a citizen of the People’s Republic of China. To the best of the Directors’ knowledge, information and belief after having made all reasonable enquiries, Mr. Zhang is an independent third party of the Company and Mr. Zhang does not have any relationship with Mr. Wang. Accordingly, the ultimate beneficial owner of Tianjin Huyanglin is Mr. Wang.

(iii) The shareholdings of other equity holders in Tianjin Alpha are 13.3649%, which is held by Ms. Tian Yingfang (“**Ms. Tian**”) as to 10.9938% and Mr. Zhang Hongda as to 2.3711% respectively. Ms. Tian and Mr. Zhang Hongda are citizens of the People’s Republic of China. To the best of the Directors’ knowledge, information and belief after having made all reasonable enquiries, Ms. Tian and Mr. Zhang Hongda are independent third parties of the Company, and Ms. Tian and Mr. Zhang Hongda have no relationship with Mr. Wang.

By order of the Board  
**Tianjin TEDA Biomedical Engineering Company Limited**  
**Sun Li**  
*Chairman*

Tianjin, the PRC  
3 January 2022

*As at the date of this announcement, the executive directors of the Company are Ms. Sun Li, Mr. Hao Zhihui and Mr. He Xin respectively; the non-executive directors of the Company are Mr. Cao Aixin, Dr. Li Ximing and Ms. Li Xueying respectively; the independent non-executive directors of the Company are Mr. Li Xudong, Mr. Wang Yongkang and Ms. Gao Chun respectively.*

*This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors of the Company, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*The announcement will remain at the “Latest Company Announcements” page on the GEM website at [www.hkgem.com](http://www.hkgem.com) for at least seven (7) days from the date of its posting, and it will also be published and remain on the website of the Company at [www.bioteda.com](http://www.bioteda.com).*